Mixed-reality tests to measure functional mobility in adults with type 2 diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the validity and reliability of mixed reality-based functional performance assessments in adults with type 2 diabetes. The focus is on commonly used mobility tests such as the 6-minute walk, Timed Up and Go, and the sit-to-stand test, adapted for a mixed reality setting. Participants will perform these tests to determine if the mixed reality approach provides stable, clinically meaningful measurements across repeated sessions. The study is conducted at Selcuk University and targets adults aged 18 to 65 without recent structured exercise, ensuring safety and comprehension of test instructions in Turkish. Findings could support standardized, tech-assisted mobility monitoring in diabetes care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with Type 2 Diabetes Mellitus by a physician,
* Aged between 18 and 65 years,
* Ability to ambulate independently without the use of an assistive device,
* No participation in a structured exercise program within the previous 6 months,
* Cognitive ability sufficient to understand and follow test instructions,
* Visual, auditory, and vestibular functions sufficient to tolerate mixed reality applications,
* Ability to read, understand, and follow instructions in Turkish,
* Willingness to participate voluntarily in the study and provision of written informed consent.

Exclusion Criteria:

* Presence of proliferative diabetic retinopathy or severe non-proliferative diabetic retinopathy,
* Advanced peripheral neuropathy, active foot ulcer, Charcot foot, or significant sensory loss that may compromise safe test performance,
* Presence of peripheral arterial disease,
* Advanced renal failure, requirement for dialysis, or nephropathy that may compromise exercise safety,
* Myocardial infarction within the previous 6 months,
* Unstable ischemic heart disease or uncontrolled angina,
* Resting blood pressure greater than 160/100 mmHg,
* Presence of severe musculoskeletal, neurological, or vestibular disorders that may interfere with safe test performance,
* High risk of balance loss or spatial disorientation in the mixed reality environment due to visual, auditory, or balance impairments,
* Cognitive, behavioral, or compliance-related problems that may prevent completion of the study procedures.

Where it's running

• Selcuk University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation
  Konya, Selcuklu, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Mehmet K ALTUNOK, PHD(c) in PT
• Email: mehmetkaan.altunok@selcuk.edu.tr
• Phone: 5558175133

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lifestyle change program to help type 2 diabetes go into remission in Pakistan

  This study tests whether a structured, plant-predominant lifestyle program can put adults with type 2 diabetes in Lahore, Pakistan into remission for the first six months.

  Recruiting at 2 sites Green International University · Lahore, Punjab Province and 1 other locations · NCT07912944

• Colchicine for preventing cardiovascular disease in adults with type 2 diabetes

  A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.

  Recruiting Phase 2 Tan Tock Seng Hospital · Singapore, Singapore · NCT07837934

• MWN105 injection in overweight or obese adults you may join

  This early-phase trial tests whether MWN105 is safe and tolerable in overweight or obese adults in China, using a placebo comparison.

  Recruiting Phase 1 Shanghai Minwei Biotechnology Co., Ltd · Kunming, Yunnan · NCT07803809

• MWN109 tablets in adults with type 2 diabetes mellitus

  A phase 2 trial tests MWN109 tablets versus placebo (and against active control semaglutide) to see if the medicine helps adults with type 2 diabetes lower their blood sugar.

  Recruiting Phase 2 Shanghai Minwei Biotechnology Co., Ltd · Beijing, Beijing Municipality · NCT07801820

• Brain-heart axis in adults with type 2 diabetes

  This study tests how brain activity and heart regulation relate to metabolic status in adults with type 2 diabetes to understand cognitive and functional health.

  Recruiting Hacettepe University · Tunceli · NCT07757308

• Digital dietary help for people on GLP-1 therapy to reach better blood sugar and weight

  This trial tests whether adding a digital dietary program (NutriSteppe) to usual care helps adults on GLP-1 medications see better blood sugar control and weight results.

  Recruiting Kazakh Academy of Nutrition · Almaty · NCT07728669

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.